Amneal Pharmaceuticals reports Q3 adjusted EPS 19c, consensus 11c

Reports Q3 revenue $620M, consensus $585.69M. “We are pleased to report strong double-digit revenue and adjusted EBITDA growth for Q3 and raise our full year guidance. The acceleration in our growth is a testament to the strong execution of our strategy, the success of our new launches and the continued diversification of our portfolio. We are on-track to launch more than 40 new generic products in 2023, our new biosimilars are outperforming, and IPX203 for Parkinson’s remains on-track to launch in 2024. Looking ahead, we expect continued strong growth and momentum across our business. With the organic growth engine set, we are focused on further deleveraging and driving value creation for shareholders,” said Chirag and Chintu Patel, Co-CEOs.